
Life Sciences Corporate Governance and Disclosure

Life Sciences

Benefitting our life sciences clients, we are able to offer disclosure and corporate governance insight that has been developed by serving as outside counsel to hundreds of US and non-US public companies, including many life sciences companies, that regularly seek our advice on sensitive and critical governance and disclosure questions; and through our leading Capital Markets Practice. With a team that includes former SEC senior staff members, our lawyers provide a unique combination of substantive knowledge, practical experience and skill.

Our corporate lawyers draw on the firm's preeminent securities enforcement and regulatory practices when clients encounter corporate crises (related to disclosure, whistleblower complaint or internal investigation) or need guidance on important public policy issues. This close collaboration enables us to assist clients with disclosure, governance and compliance issues based on real, multi-disciplinary experience with similar situations, our deep knowledge of the life sciences industry and with an in-depth understanding of the SEC's current thinking on key issues. We work closely with clients to address new disclosure requirements, technical compliance developments, and emerging hot-button governance and disclosure issues. We advise on SEC and stock exchange requirements, shareholder proposals, corporate governance practices, anti-takeover defenses, investor expectations and emerging best practices, and address interactions with activist shareholders.

Key Contacts



Lillian Brown

PARTNER

 lillian.brown@wilmerhale.com

 WASHINGTON DC

 + 1 202 663 6743



Cynthia T. Mazareas

PARTNER

✉ cynthia.mazareas@wilmerhale.com

📍 BOSTON

☎ + 1 617 526 6393



Rosemary G. Reilly

PARTNER

✉ rosemary.reilly@wilmerhale.com

📍 BOSTON

☎ + 1 617 526 6633
